Skip to main navigation
Logo

Live - Corprorate Menu

  • About Us
    • History
    • Our Leadership
    • Collaborations
    • Compliance and Ethics
    • Corporate Giving
  • Our Focus
    • Cerebral Adrenoleukodystrophy
    • Multiple Myeloma
    • Sickle Cell Disease
    • Transfusion Dependant Beta-Thalassemia
  • Our Science
    • What is Gene Therapy?
    • Gene Therapy Techniques
    • Clinical Trials
    • Our Pipeline
  • Our Products
  • Patients & Advocacy
    • Patient Advocacy
    • Patient Resources
    • Access Policy

Live - Top Nav

  • investors & media
  • contact us
  • careers
  • stories

Investors & Media

Overview Corporate Governance Press Releases Events & Presentations Analyst Coverage Stock Information SEC Filings Investor FAQs

Toolkit

  • Annual Meeting
  • Information Request
  • Corporate Presentation
  • Our Value Model
  • Sign Up for Email Alerts
  • RSS Feeds

Media Contacts

  • Jenn Snyder

    VP, Corporate Communications

    (617) 448-0281

    JSnyder@bluebirdbio.com

  • Catherine Falcetti

    Senior Director, Corporate Communications

    (339) 499-9436

    CFalcetti@bluebirdbio.com

Investor Contacts

  • Ingrid Goldberg

    VP, Investor Relations

    (857) 217-0490

    IGoldberg@bluebirdbio.com

  • Elizabeth Pingpank

    Director, Investor Relations

    (617) 914-8736

    EPingpank@bluebirdbio.com

bluebird bio to Present Data from Gene and Cell Therapy Programs During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

  • Read more about bluebird bio to Present Data from Gene and Cell Therapy Programs During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

bluebird bio Reports Third Quarter 2020 Financial Results and Highlights Operational Progress

  • Read more about bluebird bio Reports Third Quarter 2020 Financial Results and Highlights Operational Progress

Difei Yang, Ph.D.

    Difei Yang, Ph.D.
    Mizuho Securities

    bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD)

    • Read more about bluebird bio Announces European Medicines Agency’s Acceptance of Marketing Authorization Application (MAA) for elivaldogene autotemcel (eli-cel, Lenti-D™) Gene Therapy for Cerebral Adrenoleukodystrophy (CALD)

    Jefferies Cell Therapy Summit

    • Read more about Jefferies Cell Therapy Summit

    bluebird bio to Present at Jefferies Cell Therapy Virtual Summit

    • Read more about bluebird bio to Present at Jefferies Cell Therapy Virtual Summit

    bluebird bio’s LentiGlobin™ for Sickle Cell Disease Gene Therapy (bb1111) Granted Priority Medicines (PRIME) Designation by European Medicines Agency

    • Read more about bluebird bio’s LentiGlobin™ for Sickle Cell Disease Gene Therapy (bb1111) Granted Priority Medicines (PRIME) Designation by European Medicines Agency

    U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)

    • Read more about U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)

    BofA Global Healthcare Conference 2020

    • Read more about BofA Global Healthcare Conference 2020

    Morgan Stanley 18th Annual Global Healthcare Conference

    • Read more about Morgan Stanley 18th Annual Global Healthcare Conference

    Pagination

    • First page « First
    • Previous page ‹ Previous
    • Page 1
    • Current page 2
    • Page 3
    • Page 4
    • Page 5
    • Page 6
    • Page 7
    • Page 8
    • Page 9
    • …
    • Next page Next ›
    • Last page Last »
    Subscribe to

    Quick Links

    • Patients & Advocacy
    • Investors & Media
    • Careers
    • Contact Us

    CONTACT INFO

    info@bluebirdbio.com

    clinicaltrials@bluebirdbio.com

    investor@bluebirdbio.com

    medinfo@bluebirdbio.com

    Live - Terms & Privacy

    • Terms of Service
    • Privacy Policy
    • Cookie Notice
    • Sitemap
    © 2021 bluebird bio, Inc. All Rights Reserved. Corp-GBL-00011 05/19

    Live - Social Links